Interestingly, AML but not breast cancer patients showed significantly increased blood plasma levels of TGF-β (Figure 3), which suggests that in breast (solid) tumours TGF-β remains within tumour microenvironment, while in AML it is secreted into the blood thus having the opportunity to systemically act on AML cells in circulation. Here, TGFB1 is linked to neoplasm.